Merck & Company, Inc. Press Releases

MRK 
$55.31
*  
0.57
1.02%
Get MRK Alerts
*Delayed - data as of Jun. 27, 2016  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
6/27/2016 6:00:00 AM - Business Wire
▼-0.98 % Price Change since this news event. The Volume Ratio is 1.62.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
6/24/2016 8:00:00 AM - Business Wire
▼-1.37 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Roger Ulrich Joins Board of Remedy Pharmaceuticals
6/21/2016 10:00:00 AM - Business Wire


Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
6/20/2016 12:30:00 PM - Business Wire
▼-2.05 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
6/16/2016 8:00:00 AM - Business Wire
▼-3.13 % Price Change since this news event. The Volume Ratio is 2.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
6/16/2016 6:45:00 AM - Business Wire
▼-1.39 % Price Change since this news event. The Volume Ratio is 2.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
6/15/2016 8:30:00 AM - Business Wire
▼-1.58 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
6/13/2016 11:00:00 AM - PR Newswire
▼-2.14 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
6/13/2016 10:30:00 AM - Business Wire
▼-2.05 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
6/11/2016 11:00:00 AM - Business Wire
▼-1.74 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Acquire Afferent Pharmaceuticals
6/9/2016 6:34:00 PM - Business Wire
▼-3.13 % Price Change since this news event. The Volume Ratio is 1.44.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
6/6/2016 8:00:00 AM - Business Wire
▼-2.96 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
6/6/2016 8:00:00 AM - Business Wire
▼-2.96 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
6/5/2016 1:43:00 PM - Business Wire
▼-2.33 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
6/5/2016 8:00:00 AM - Business Wire
▼-2.33 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
6/4/2016 8:00:00 AM - Business Wire
▼-2.33 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
6/4/2016 8:00:00 AM - Business Wire
▼-2.33 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
6/1/2016 5:00:00 PM - Business Wire
▼-1.81 % Price Change since this news event. The Volume Ratio is 1.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Announces Third-Quarter 2016 Dividend
5/24/2016 2:35:00 PM - Business Wire


Merck Announces Third-Quarter 2016 Dividend
5/24/2016 2:35:00 PM - Business Wire
▼-0.70 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck to Present at the UBS Global Healthcare Conference
5/24/2016 8:00:00 AM - Business Wire
▲0.71 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution for Cats and Dogs
5/24/2016 6:19:00 AM - Business Wire
▲0.71 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day